LifeVantage (LFVN) investor relations material

Strategic priorities and brand differentiation

• Focus on strengthening brand by emphasizing unique approach: enabling the body to produce key substances rather than supplementing directly.

• Highlighting clinically proven products and next-generation science as competitive advantages.

• Plans to improve messaging, packaging, and digital presence to better communicate product benefits.

• Intention to sharpen pricing and consider reformulation or repackaging to maintain high margins.

Operational efficiency and profitability

• Recent top-line deterioration impacted operating and EBITDA margins due to loss of scale.

• Initiatives underway to maintain gross margins near 80% through supply chain and logistics improvements.

• SG&A reduced by about $10 million (15%), with further efficiency gains targeted via technology and automation.

• Emphasis on smarter, not just smaller, organization; leveraging AI and automation for productivity.

• Focus on growing revenue through improved brand and consumer relevance rather than cost-cutting alone.

Product and market strategy

• Flagship Protandim line positioned around cellular defense, energy, and longevity, with plans to enhance consumer messaging.

• MindBody GLP-1 product saw initial explosive growth, followed by decline due to competition and lack of new customer acquisition.

• Future growth for MindBody expected through improved positioning, pricing, and digital marketing over the next 12 months.

• Plans to adopt elements of omni-channel and digital strategies from prior leadership experience, tailored to current strengths.